Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction

Liver Int. 2011 Oct;31(9):1315-24. doi: 10.1111/j.1478-3231.2011.02602.x. Epub 2011 Aug 2.

Abstract

Background: Mitochondria are the main sites for fatty acid oxidation and play a central role in lipotoxicity and nonalcoholic steatohepatitis.

Aims: We investigated whether carnitine prevents free fatty acid (FFA)-induced lipotoxicity in vitro and in vivo.

Methods: HepG2 cells were incubated with FFA, along with carnitine and carnitine complexes. Mitochondrial β-oxidation, transmembrane potential, intracellular ATP levels and changes in mitochondrial copy number and morphology were analysed. Otsuka Long-Evans Tokushima Fatty and Long-Evans Tokushima Otsuka rats were segregated into three experimental groups and fed for 8 weeks with (i) normal chow, (ii) a methionine choline-deficient (MCD) diet or (iii) an L-carnitine-supplemented MCD diet.

Results: Carnitine prevented FFA-induced apoptosis (16% vs. 3%, P < 0.05). FFA treatment resulted in swollen mitochondria with increased inner matrix density and loss of cristae. However, mitochondria co-treated with carnitine had normal ultrastructure. The mitochondrial DNA copy number was higher in the carnitine treatment group than in the palmitic acid treatment group (375 vs. 221 copies, P < 0.05). The carnitine group showed higher mitochondrial β-oxidation than did the control and palmitic acid treatment groups (597 vs. 432 and 395 ccpm, P < 0.05). Carnitine treatment increased the mRNA expression of carnitine palmitoyltransferase 1A and peroxisome proliferator-activated receptor-γ, and carnitine-lipoic acid further augmented the mRNA expression. In the in vivo model, carnitine-treated rats showed lower alanine transaminase levels and lesser lobular inflammation than did the MCD-treated rats.

Conclusions: Carnitine and carnitine-lipoic acid prevent lipotoxicity by increasing mitochondrial β-oxidation and reducing intracellular oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Apoptosis / drug effects
  • Carnitine / analogs & derivatives
  • Carnitine / pharmacology*
  • Carnitine O-Palmitoyltransferase / genetics
  • Carnitine O-Palmitoyltransferase / metabolism
  • Choline Deficiency / complications
  • DNA, Mitochondrial / metabolism
  • Disease Models, Animal
  • Fatty Acids, Nonesterified / metabolism*
  • Fatty Liver / etiology
  • Fatty Liver / genetics
  • Fatty Liver / metabolism
  • Fatty Liver / pathology
  • Fatty Liver / prevention & control*
  • Gene Expression Regulation / drug effects
  • Hep G2 Cells
  • Humans
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology
  • Lysosomes / drug effects
  • Lysosomes / metabolism
  • Membrane Potential, Mitochondrial / drug effects
  • Methionine / deficiency
  • Mitochondria, Liver / drug effects*
  • Mitochondria, Liver / metabolism
  • Mitochondria, Liver / pathology
  • Non-alcoholic Fatty Liver Disease
  • Oxidation-Reduction
  • Oxidative Stress / drug effects
  • PPAR gamma / genetics
  • PPAR gamma / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred OLETF
  • Rats, Long-Evans
  • Thioctic Acid / analogs & derivatives
  • Thioctic Acid / pharmacology*
  • Time Factors

Substances

  • DNA, Mitochondrial
  • Fatty Acids, Nonesterified
  • PPAR gamma
  • RNA, Messenger
  • Thioctic Acid
  • Adenosine Triphosphate
  • Methionine
  • Carnitine O-Palmitoyltransferase
  • Carnitine